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TDP-43 is a predominantly nuclear RNA-binding protein that forms inclusion 
bodies in frontotemporal lobar degeneration (FTLD) and amyotrophic lateral 
sclerosis (ALS). The mRNA targets of TDP-43 in the human brain and its role in 
RNA processing are largely unknown. Using individual-nucleotide resolution UV-
crosslinking and immunoprecipitation (iCLIP), we demonstrated that TDP-43 
preferentially binds long clusters of UG-rich sequences in vivo. Analysis of TDP-43 
RNA binding in FTLD-TDP brains revealed the greatest increases in binding to 
MALAT1 and NEAT1 non-coding RNAs. We also showed that TDP-43 binding on 
pre-mRNAs influences alternative splicing in a similar position-dependent manner 
to Nova proteins. In addition, we identified unusually long clusters of TDP-43 
binding at deep intronic positions downstream of silenced exons. A significant 
proportion of alternative mRNA isoforms regulated by TDP-43 encode proteins that 
regulate neuronal development or are implicated in neurological diseases, 
highlighting the importance of TDP-43 for splicing regulation in the brain. 
TAR DNA binding protein (TDP-43) is a predominantly nuclear protein reported to 
regulate transcription, alternative splicing and RNA stability1,2. TDP-43 has two RNA-
recognition motif (RRM) domains, which bind UG repeat sequences with high affinity3. 
TDP-43 mislocalisation and aggregation is implicated in the pathogenesis of amyotrophic 
lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD-TDP). Mutations in the 
gene encoding TDP-43 are associated with 1-4% of familial and sporadic ALS and rare 
FTLD cases, and confer toxicity4,5. The pathology of ~60% of FTLD and ~90% of ALS 
cases are characterised by the formation of cytoplasmic inclusion bodies in neurons and 
astroglia that are rich in ubiquitinated, hyperphosphorylated C-terminal fragments of 
TDP-435,6. Neurons containing cytoplasmic TDP-43 inclusions often have dramatically 
reduced TDP-43 staining in the nucleus5,6. Thus, TDP-43 inclusions might have a toxic 
gain of function in the cytoplasm and/or sequester nuclear TDP-43, disrupting its role in 
RNA processing. TDP-43 cleavage products found in the cytoplasmic inclusions have 
been shown to alter splicing of a TDP-43 regulated exon in minigene studies, indicating 
that they are capable of interfering with wild-type TDP-43 function7. The toxicity of 
TDP-43 overexpression is dependent on retaining its RNA binding function in yeast8, 
drosophila and chick9. 
To date, only a handful of RNAs regulated by TDP-43 have been identified. In order to 
understand the function of TDP-43, and its dysfunction in disease, we have 
comprehensively identified the RNA sites interacting with TDP-43 in human brain and 
characterised changes in RNA following reduced TDP-43 expression. In order to identify 
RNA targets on a global scale, we used individual-nucleotide resolution CLIP (iCLIP), 
which captures truncated cDNAs and quantifies them using a random barcode contained 
within the primer used for reverse transcription10. Duplicate sequences sharing the same 
random barcode were removed from analysis in order to avoid any apparent binding-site 
bias due to PCR artefacts. 
In this study, we sought to identify the RNAs bound by TDP-43 in the healthy and FTLD 
brain tissue containing TDP-43 inclusions (FTLD-TDP). Although this was the first study 
of protein-RNA interactions in post-mortem human brain, we identified a high number of 
RNA binding sites using these samples. Most binding mapped to introns, long ncRNAs 
and intergenic transcripts, which also had the greatest enrichment of UG-rich motifs. We 
characterised the changes in alternative splicing following TDP-43 knockdown in 
neuroblastoma cells and identified splicing changes in 158 alternative cassette exons. 
Analysis of TDP-43 iCLIP crosslink sites in the vicinity of these exons provided insights 
into the mechanisms of TDP-43 splicing regulation. The exons regulated by TDP-43 are 
enriched in genes involved in neuronal development and those implicated in a range of 
neurodegenerative diseases. 
 
RESULTS 
Comparison of TDP-43 binding between healthy and FTLD-TDP brains. 
TDP-43 in complex with its direct RNA targets was purified from UV-crosslinked cells 
and analysed on SDS-PAGE gel. The size of the dominant TDP-43-RNA complex 
present in the low and high RNase conditions corresponded to a single TDP-43 molecule 
bound to the RNA, however a complex corresponding to two TDP-43 molecules bound to 
the RNA was also present, particularly in the low RNase experiment (Fig. 1a). This result 
agreed with the finding of a past study that TDP-43 binds RNA as a homodimer2. 
iCLIP experiments were performed with human cortical tissue from human post-mortem 
brain samples of three cognitively normal (healthy) and three sporadic FTLD-TDP 
patients, as well as from embryonic stem cells (hES) and SH-SY5Y neuroblastoma cells 
(Supplementary Table 1). In total, 17 million sequence reads aligned as single hits to the 
human genome by allowing a maximum of one nucleotide mismatch. After eliminating 
PCR amplification artefacts by removing sequences that truncated at the same nucleotide 
in the genome and shared the same random barcode, 3,7 million reads representing 
unique cDNA molecules were identified (Supplementary Table 2). 
Genomic annotation of the cDNA sequences showed that the majority of TDP-43 binding 
occurred in introns, 74% in the cell lines and 58% in brain samples (Fig. 1b). The 
decreased proportion in brain samples, and corresponding increase in exonic sequences, 
may be a result of a greater sensitivity of intronic RNA to degradation in postmortem 
samples. Approximately 5% of iCLIP cDNAs mapped to long ncRNAs in all samples 
(Fig. 1c). Increased binding of TDP-43 to snoRNAs, snRNAs, rRNAs and telomeric 
ncRNAs was seen in FTLD-TDP (Fig. 1c). In total, 2139 ncRNA genes contained a 
crosslink site in control and 2702 in FTLD-TDP experiments. 
The high proportion of intronic cDNA sequences indicated that the iCLIP data mainly 
represent nuclear RNA targets of TDP-43. To further evaluate this, we quantified the 
crosslinked complexes that were obtained using the iCLIP procedure from nuclear and 
cytoplasmic fractions of healthy and FTLD-TDP brain tissue. Only 6.5% of the total 
TDP-43-RNA complexes were obtained from cytoplasmic fractions of brain tissue, with 
insignificant difference between healthy and FTLD-TDP tissues (Supplementary Fig. 1b). 
iCLIP analysis of the RNAs bound by TDP-43 in the two fractions in SH-SY5Y cells 
showed 34% 3’UTR binding in the cytoplasm, 3.2% in the nuclear fraction and 3.8% in 
total cell extract (Supplementary Fig. 1d, Fig. 1b). As a control, we analysed crosslink 
complexes with TIAL1, a protein that is known to shuttle between nucleus and 
cytoplasm. 31.5% of total TIAL1-RNA crosslinked complexes were obtained from 
cytoplasmic fractions of healthy and FTLD-TDP brain tissue (Supplementary Fig. 1b). 
Thus, even though the TIAL1 analysis demonstrates that iCLIP can efficiently purify 
proteins bound to cytoplasmic RNAs, our analysis indicates that over 93% of TDP-43 
iCLIP data presented in this study represents interactions with nuclear RNAs both in 
healthy and FTLD-TDP brain tissue. 
To study the changes in TDP-43 binding to individual transcripts in FTLD-TDP, we 
analysed the proportion of cDNAs mapping to individual co-expressed genomic regions 
in the different brain samples. A significant (p value < 0.05 by Student's t-test, one-tailed, 
unequal variance) and greater than 0.025% change in proportion of cDNAs between 
control and FTLD-TDP brain was found in four ncRNAs, 3’ UTRs of seven transcripts 
and introns of 48 transcripts (Supplementary Table 3). The fact that introns had the 
greatest number of changes indicates that the changes detected by iCLIP mainly reflect 
changes in RNA interactions that occur in cell nuclei. 
Four transcripts had a significant and greater than 0.1% change in proportion of cDNAs  
(p value < 0.05, Fig. 1d). Analysis of the abundance of these transcripts by RNA-seq and 
real-time PCR showed that the change in TDP-43 binding agreed with a similar extent of 
change in transcript expression (Fig. 1e, Supplementary Fig. 2). The most significant 
increase in TDP-43 binding in FTLD-TDP was observed in the nuclear paraspeckle 
assembly transcript 1 (NEAT1) and the metastasis associated lung adenocarcinoma 
transcript 1 (MALAT1, also known as NEAT2), which are transcribed from proximal loci 
on chromosome 11. Whereas NEAT1 was previously identified as a 4 kb long ncRNA11, 
we detected TDP-43 binding along the length of a 18kb ncRNA, with the peak binding in 
a tandem UG-repeat sequence close to the 3’ end (Fig. 1d, f). The primary binding sites 
in these two ncRNAs contained long UG repeats, and were identified in a highly 
reproducible manner (Fig. 1f, Supplementary Fig. 1f). The neurexin 3 (NRXN3) transcript 
and the glial excitatory amino acid transporter-2 (EAAT2, also SLC1A2) had significantly 
decreased cDNA proportion in FTLD-TDP (Fig. 1d, g). EEAT2 is necessary for 
glutamate clearance at the synapse, a process that prevents glutamate excitotoxicity12. 
 
TDP-43 binds to clusters of UG-rich sequences 
In order to compare the RNA sequence specificity of TDP-43 in the different iCLIP 
experiments, we assessed the enrichment of all possible pentamers within 30 nt on either 
side of all crosslink sites. In all iCLIP data sets, the most significantly enriched pentamers 
were GUGUG and UGUGU (Fig. 2a, Supplementary Fig. 3a-c). The pentamer 
enrichment scores were correlated between healthy and FTLD-TDP brain (r=0.91, Fig. 
2a).  
We analysed the relationship between TDP-43 binding and UG repeats length by 
monitoring the frequency of crosslinking in the last ten nucleotides of UG tandem repeats 
compared to randomised positions. An example of a UG tandem repeat can be seen in the 
NEAT1 ncRNA (Fig. 1f). We found that enrichment of TDP-43 crosslinking to UG 
repeats increased up to a repeat length of 15 nt, in a manner that was similar in healthy 
and FTLD-TDP brain (Fig. 2b, c). For comparison, we performed iCLIP with CELF2, 
which also binds UG-rich motifs in the human brain (Supplementary Fig. 3c). In contrast 
to TDP-43, binding of CELF2 to UG repeats increased only up to a length of 10 nt, and 
dropped once the repeats became longer than 15 nt (Fig. 2b). This indicates that TDP-43 
has a stronger preference for tandem UG repeats compared to CELF2. 
Proteins interacting with multiple identical sequences on the RNA often allow spacing 
between different binding sites; for instance, NOVA proteins bind clusters of a minimum 
of three YCAY tetramers, but can tolerate variable spacing between these13. To analyse if 
TDP-43 can similarly bind to more dispersed UG-rich motifs, we monitored the 
frequency of UGUGU motifs over a 200 nt region surrounding the TDP-43 crosslink sites 
compared to randomised positions. UGUGU was seven-fold enriched at the TDP-43 
crosslink sites, and remained two-fold enriched even at a distance of 100 nts away from 
the crosslink sites (Fig. 2d, e). One cause for this phenomenon may be a tendency of 
TDP-43 to bind to long UG-rich RNA regions, such as the 90 nucleotide region in the 3’ 
UTRs of TARDBP mRNA, where TDP-43 binds to autoregulate its own mRNA levels 
(Fig. 2f)14,15. In contrast, even though UGUGU is four-fold enriched at the CELF2 
crosslink sites, no such enrichment was seen at a distance of 100 nts (Fig. 2d). This 
indicates that TDP-43 has a unique capacity to recognise dispersed clusters of UG-rich 
motifs, or to spread its RNA binding to positions proximal to the UG-rich motifs. 
To specifically analyse the high-affinity RNA binding sites of TDP-43, we grouped all 
data and searched for crosslink sites clustered with a maximum spacing of 15 nt that 
contained a significant cDNA count when compared to randomised positions (FDR < 
0.05). 111,691 such crosslink clusters were identified. The reproducibility of crosslinking 
within these clusters between different samples increased with the number of iCLIP 
cDNA sequences that mapped to a cluster (Supplementary Fig. 3 d-g). For instance, 76% 
of clusters with summed cDNA counts of five or more in healthy brain were similarly 
bound in FTLD (Supplementary Fig. 3d). Clustered crosslink sites were highly enriched 
in UG tandem repeats, with increased enrichment at repeat lengths up to 30 nts (Fig. 2c). 
UGUGU was 18-fold enriched at the TDP-43 crosslink sites, and remained five-fold 
enriched even at a distance of 100 nts away from the crosslink sites (Fig. 2e). The 
increased incidence of UG-rich motifs at the crosslink clusters confirms that these 
clusters are the likely high-affinity binding sites of TDP-43. 
To compare TDP-43 binding to different types of RNAs, we analysed the enrichment of 
UGUGU motif at the crosslink sites. The rRNAs, snRNAs, tRNAs and snoRNAs had the 
lowest UGUGU enrichment, indicating that crosslinking in these RNAs mainly reflected 
low-affinity, transient interactions (Supplementary Fig. 4). Three-fold enrichment was 
seen in 5’UTRs and ORFs, and four-fold UG enrichment was seen in 3’ UTRs, miRNA 
precursors and telomeric transcripts (Supplementary Fig. 4). Similar UG enrichment was 
seen in the 3’ UTRs when isolated with nuclear or cytoplasmic mRNA, indicating that 
TDP-43 binds to RNA in sequence-specific manner both in nucleus and the cytoplasm 
(Supplementary Fig. 1e). Seven-fold enrichment of UGUGU pentamers was seen in 
introns, long ncRNAs and intergenic RNAs, which together contain most TDP-43 
binding (90% in cell lines and 76% in brain samples, Fig 1b, c). The high UG enrichment 
in intergenic RNAs is particularly interesting, indicating that high-affinity TDP-43 
interactions occur with a large number of as yet non-annotated transcripts. Taken 
together, the iCLIP results indicate that TDP-43 binds pre-mRNAs and several types of 
ncRNAs in a sequence-specific manner. 
 
The TDP-43 RNA splicing map 
As the majority of iCLIP cDNAs mapped to introns, we reasoned that TDP-43 might 
have an important role in splicing regulation. Therefore, we used Affymetrix high-
resolution splice-junction microarrays to evaluate splicing changes in TDP-43 
knockdown SH-SY5Y cells. Analysis of splicing isoform reciprocity using the ASPIRE3 
software identified splicing changes in 158 alternative cassette exons and 71 other types 
of splicing changes (⏐∆Irank⏐≥1) out of 30154 alternative exons that were detected by 
the microarray. 40 of the cassette exons were further assessed using RT-PCR and 
capillary electrophoresis. For 32 splicing events, primer pairs generated both isoforms, 
and 28 of these reproduced the direction of the observed splicing change, resulting in a 
87% (28/32) validation rate of the microarray data (Supplementary Table 4). 
To study how TDP-43 binds pre-mRNAs to regulate splicing, we visualised the positions 
of crosslink clusters in the form of an RNA splicing map, where the crosslink sites are 
plotted within 500 nt of the silenced (blue clusters) or enhanced (red clusters) cassette 
exons and the flanking exons (Fig. 3). The crosslink clusters identified three regions on 
the RNA splicing map where TDP-43 binding was mainly restricted to silenced or 
enhanced exons (Fig. 3). Binding in the region 1, 0-150 nt upstream or within the 
alternative exons, was present at 11 silenced and 1 enhanced exon (group S1). Binding in 
the region 2, 150-500 nt downstream of the alternative exons, was present at 7 silenced 
and 1 enhanced exon (group S2). Five of the silenced exons contained multiple crosslink 
clusters that spanned a sequence of 100 nt or longer in this region. This indicates that 
‘deep’ intronic binding involving multiple dispersed binding sites might contribute to the 
ability of TDP-43 to silence exon inclusion. Finally, binding in the region 3, 0-150 nt 
downstream of the alternative exons (but not region 1 or 2), was present at four enhanced 
exons (group E). 
To evaluate the proportion of TDP-43 iCLIP targets that changed splicing after 
knockdown, we analysed splicing of exons with crosslink clusters in the three regions 
defined by the RNA splicing map. We used RT-PCR to evaluate splicing of 41 putative 
alternative exons that had highest number of cDNAs mapping to these regions. 29% 
(12/41) of these exons showed no evidence of alternative splicing in SH-SY5Y cells 
(single band detected by RT-PCR). 79% (23/29) of the remaining exons changed splicing 
after knockdown, indicating that iCLIP data alone has high predictive value 
(Supplementary Table 4, Supplementary Fig. 5b). We also assayed splicing of 12 
alternative exons that had UG-rich regions within 200 nt of the alternative exons, but 
were not identified either by microarray or iCLIP. A splicing change in 5 of these exons 
was validated by RT-PCR (Supplementary Table 4). Similar to the iCLIP binding, UG-
rich motifs upstream of the exon or dispersed motifs downstream of the exon were 
associated with silencing, whereas proximal UG-rich motifs downstream of the exon 
were associated with enhancing function of TDP-43 (Supplementary Fig. 5c). 
 
TDP-43 regulates splicing of mRNAs involved in neuronal development 
TDP-43 crosslink clusters were also present in introns of 7,499 protein-coding genes and 
3’ UTRs of 1,172 genes. 67% of the genes with 3' UTR clusters (785/1,172) also had 
intronic clusters. For instance, two crosslink clusters were present in the intron 
downstream of the alternative exon 11 and three clusters in the 3’ UTR of myocyte 
enhancer factor 2D (MEF2D) mRNA (Fig. 4a). We identified a 29% decrease in 
inclusion of the MEF2D exon 11 in TDP-43 knockdown SH-SY5Y cells (Fig. 4a). The 
additional binding sites in the 3’ UTR indicate that TDP-43 can remain associated with 
the MEF2D mRNA after splicing is finished and thereby regulate additional aspects of 
RNA processing. 
Due to the strong sequence-specificity in binding to long ncRNAs (Supplementary Fig. 
4), we also speculated that TDP-43 might regulate processing of such ncRNAs. iCLIP 
identified an alternative exon in the long ncRNA myocardial infarction associated 
transcript (MIAT). Eleven crosslink clusters are dispersed over the 1 kb region of both 
introns that flank this exon (Fig. 4b). We identified a 43% decrease in inclusion of the 
MIAT exon 10 in TDP-43 knockdown SH-SY5Y cells (Fig. 4b, Supplementary Fig. 5b). 
We also identified a crosslink cluster in the CFTR pre-mRNA, which was the first 
identified RNA target of TDP-433. Importantly, the crosslink overlapped with the UG-
rich element upstream of exon 9, which is required for TDP-43-dependent splicing 
regulation of this exon (Supplementary Fig. 6). Past studies identified several candidate 
RNA targets of TDP-43, for which the direct in vivo interaction with TDP-43 has not 
been validated. Here, we identified TDP-43 binding sites in the FUS pre-mRNA16, hNFL 
3' UTR17, the CDK6 intron and 3' UTR18, and the intronic region overlapping with the 
mir558 gene19 (Supplementary Fig. 6). Also of particular interest, we observed crosslink 
clusters in the mRNAs encoding HDAC6 and Casein kinase 1 and 2, which were reported 
to regulate phosphorylation and expression of TDP-43, respectively20,21 (Supplementary 
Fig. 6). 
We performed GO term analysis of genes regulated by TDP-43 at the level of alternative 
splicing, as determined by analysis of SH-SY5Y knockdown cells. This identified several 
terms related to development, including neural tube formation, organ morphogenesis and 
chordate embryonic development (Table 1). 15 of the exons regulated by TDP-43 are 
within genes encoding proteins with well-characterised functions in neuronal survival or 
development (Table 2). TDP-43 promotes inclusion of alternative exon 3 in Bcl-2 
interacting mediator of cell death (BIM, also BCL2l11), and thereby suppresses 
production of the most cytotoxic BIM isoform (BIMS)22. We have evaluated splicing of 
BIM in FTLD-TDP, and have found that the BIMS isoform increases in FTLD-TDP 
tissue to a similar extent as in TDP-43 knockdown cells (Fig. 4c). This result indicates 
that aberrant splicing might contribute to the neurodegenerative process in human brain. 
 
DISCUSSION 
Our results show that TDP-43 interacts with a diverse spectrum of RNAs with important 
functions in the brain. We identified binding of TDP-43 to non-coding RNAs, introns and 
3’ UTRs of mRNAs, indicating a role for TDP-43 in coupling different aspects of gene 
expression. Even though only a minor portion of the protein was detected in the 
cytoplasm, we found a ten-fold increase of TDP-43 binding to 3’ UTR elements when 
comparing RNAs bound to cytoplasmic and nuclear protein. We also identified the 
changes in alternative splicing associated with reduced level of TDP-43 protein. Analysis 
of crosslink clusters in the regulated pre-mRNAs indicates that the splicing function of 
TDP-43 depends on the position where it interacts with pre-mRNAs. 
We found that TDP-43 preferentially binds to UG tandem repeats or long clusters of UG-
rich motifs. These results agree with the past in vitro studies which showed that RNA 
binding of TDP-43 increases with the length of the UG repeat2,3. iCLIP results also 
indicate that the increased affinity for long binding sites differentiates the RNA 
specificity of TDP-43 from CELF2, which recognises shorter clusters of UG-rich motifs. 
Since a single RRM domain generally recognises four nucleotides23, this RNA specificity 
for long binding sites indicates that TDP-43 can cooperatively recognise multiple RNA 
binding sites and thereby achieve high-affinity RNA binding. The apparent RNA binding 
of TDP-43 in a homodimer state might contribute to its ability to recognise binding sites 
composed of multiple dispersed UG-rich motifs (Fig. 1a). 
TDP-43 crosslink clusters were located upstream and within the silenced exons and 
immediately downstream of enhanced exons, which is also a characteristic of several 
other RBPs, including the Nova proteins24. In addition, dispersed clusters of TDP-43 
crosslinking further downstream of exons were associated with splicing silencing. Similar 
mode of splicing silencing, involving multiple binding sites flanking an alternative exon, 
has also been reported for Sxl, hnRNP A1, PTB, hnRNP L and hnRNP C10,25,26. The 
glycine-rich C-terminal domain of Sxl and hnRNP A1 is required for the cooperative 
assembly of these proteins on multiple proximal binding sites and the associated splicing 
silencing25. Interestingly, TDP-43 also contains a glycine-rich C-terminus. Mutations in 
the TARDBP gene that were identified in ALS or FTLD patients are concentrated in the 
region encoding the glycine-rich C-terminus5, indicating that the ability of TDP-43 for 
cooperative assembly on long RNA binding sites plays a role in the disease mechanisms. 
The tandem UG repeat sequences recognised by TDP-43 correspond to the most common 
microsatellite (AC) in the human genome. Variation in the length of microsatellites can 
introduce heritable phenotypic variation27 or lead to changes in transcription and 
alternative splicing28. Genes involved in organ morphogenesis and neurogenesis are 
enriched in the variable tandem repeats29. Similarly, the genes containing the exons 
regulated by TDP-43 are enriched for neural tube formation and organ morphogenesis. 
This is consistent with the finding that TDP-43 knockout is lethal for mice from 
embryonic day 3.530. It could be speculated that the ability of TDP-43 to regulate splicing 
by binding the UG repeats in the human genome might contribute to variation in splicing 
regulation of genes involved in development. 
TDP-43 regulates splicing of several transcripts encoding proteins involved in neuronal 
survival, as well as seven mRNAs encoding proteins with relevance for 
neurodegenerative diseases (Table 2). Delta-catenin (CTNND1) plays a role in the 
development and maintenance of dendritic spines31,32. Furthermore, CTNND1 interacts 
with presenilin-1 to inhibit production of Aβ peptide, the main constituent of amyloid 
plaques in the brains of Alzheimer's disease patients33. MEF2D is a transcription factor 
that was reported to play a role in neuronal survival in Parkinson’s disease34. BIM is a 
core factor in the neuron-specific JNK-mediated apoptotic pathway, and loss of BIM 
protects mice from ischemia-induced damage35,36. The BIM splice isoforms regulated by 
TDP-43 have been functionally characterised; BIMS antagonizes the pro-survival Bcl-2 
family members more effectively than BIML, while BIMEL is the least potent22. We found 
that production of the most cytotoxic BIM isoform (BIMS) was increased in TDP-43 
knockdown cells and in FTLD-TDP. However, analysis of other exons regulated by TDP-
43 did not indicate a significant correlation with the splicing changes present in FTLD-
TDP (unpublished observation). 
We also found that TDP-43 binds to long ncRNAs in highly sequence-specific manner 
both in control and FTLD-TDP samples. The greatest increase in TDP-43 binding in 
FTLD-TDP is seen in the NEAT1 ncRNA. Expression of NEAT1 and MALAT1 
significantly increases in FTLD-TDP, which might be the primary cause of the increased 
association of TDP-43 with these RNAs. NEAT1 functions in paraspeckle assembly11, 
and the MALAT1 ncRNA, which recruits splicing factors to nuclear speckles and affects 
phosphorylation of SR proteins37. In conclusion, we have characterised the splicing 
function of TDP-43 and quantified the changes in its RNA binding in FTLD-TDP. 
Analysis of these RNAs in model organisms and in neurons containing TDP-43 
inclusions will be required for full understanding of the mechanisms of TDP-43 loss- or 
gain-of-function effects in the neurodegenerative process. 
  
Figure Legends 
 
Figure 1: Comparison of TDP-43 RNA binding in healthy and FTLD-TDP brain. (a) 
To validate specificity of TDP-43 antibody for iCLIP, the 32P-labelled RNA bound to 
TDP-43 gel was isolated from control (Ctr) or knockdown (KD) HeLa cells in the 
presence or absence of UV crosslinking or anti-TDP-43 antibody. High and low RNase 
concentrations were used to confirm the presence of RNA bound to TDP-43. The arrows 
mark the positions on the gel corresponding to the size of TDP-43 monomer or dimer. 
TDP-43 Western analysis of input extracts confirmed TDP-43 knockdown, and GAPDH 
was used as a loading control. The full image is shown in Supplementary Fig. 1a (b) The 
proportion of cDNAs (out of all cDNAs that mapped to human genome) from the TDP-
43 iCLIP experiments in the four types of samples that mapped to different RNA regions. 
(c) The proportion of cDNAs that mapped to different types of ncRNAs. (d) The 
proportion of cDNAs that mapped to individual RNAs with at least 10 cDNAs in any 
experiment. The RNAs with the largest significant change between control and FTLD-
TDP brain (difference in proportion of cDNAs > 0.1% and p value < 0.05 by Student's t-
test, one-tailed, unequal variance) are marked in red. The long ncRNA MEG3 
(maternally expressed 3) with the largest decrease in TDP-43 binding in FTLD-TDP is 
also marked. (e) Real-time PCR analysis of transcripts with largest TDP-43 iCLIP 
changes in total RNA isolated from control and FTLD-TDP brain samples. (f) iCLIP 
cDNA counts for TDP-43 crosslink positions in the NEAT1 gene in experiments from 
SH-SY5Y and hES cell lines, and healthy and FTLD-TDP tissue from different 
individuals. The blue bars represent sequences on the sense strand of the genome, and the 
height of the bars corresponds to the cDNA count. The positions of significant crosslink 
clusters (XL cluster) are shown on top, and the RNA sequence underlying the two man 
clusters is shown below, with UG repeats in pink. The graph shows the average 
proportion of cDNAs that map to NEAT1 transcript in each experiment (out of all cDNAs 
maping to the human genome), as well as standard deviation between experiments from 
different individuals. (g) iCLIP cDNA counts for TDP-43 crosslink positions in the 
SLC1A2 gene. The orange bars represent sequences on the antisense strand of the 
genome. The graph shows the average proportion of cDNAs that map to SLC1A2 3' UTR 
in different experiments, as well as standard deviation between experiments from 
different individuals. The RNA sequence underlying the peak crosslinking sites is shown 
below, with UG repeats in pink. 
 
Figure 2: TDP-43 binding motif analysis. (a) z-scores of penamer occurrence within 
the 61 nt sequence surrounding all crosslink sites (-30 nt to +30 nt) are shown for healthy 
and FTLD-TDP brain iCLIP. The sequences of the two most enriched pentamers and the 
Pearson correlation coefficient (r) between the two samples are given. (b) Enrichment of 
crosslinking compared to randomised data in UG repeats of different lengths in TDP-43 
iCLIP experiments from healthy brains (blue) and FTLD-TDP brains (red), and CELF2 
experiments in healthy brain (green). (d) Enrichment of crosslinking compared to 
randomised data on UG repeats of different lengths in TDP-43 iCLIP experiments from 
SH-SY5Y and hES cells, where we either included all crosslink sites (dark grey), or only 
those mapping to crosslink clusters (light grey). (e) Analysis of positions of UGUGU 
enrichment compared to randomised data around TDP-43 crosslink sites in healthy brains 
(blue) and FTLD-TDP brains (red), and CELF2 experiments in healthy brain (green). (e) 
Analysis of positions of UGUGU enrichment compared to randomised data in TDP-43 
iCLIP experiments from SH-SY5Y and hES cells, where we either included all crosslink 
sites (dark grey), or only those mapping to crosslink clusters (light grey). (f) TDP-43 
crosslinking in its own transcript (TARDBP). The replicate experiments are summed and 
shown in a single track. The RNA sequence underlying the peak crosslinking site is 
shown, with UG and GU dinucleotides in pink. 
 
Figure 3: The RNA splicing map of TDP-43. The map of crosslink clusters at positions 
within 500 nt of alternative exons and flanking exons. The cassette exons with ∆Irank > 1 
(enhanced exons, red clusters) or ∆Irank < -1 (silenced exons, blue clusters) with at least 
one crosslink cluster in these regions are shown. The exons are grouped by sequential 
analysis of crosslink cluster positions in three regions: group S1 is identified by clusters 
in region 1, 150nt upstream till the exon and within the exon; group S2 by clusters in 
region 2, 150-500nt downstream of the exon; and group E by clusters present 0-150nt 
downstream of the exon. 
 
Figure 4: TDP-43 regulates splicing of non-coding and protein-coding RNAs. (a) 
TDP-43 crosslinking in MIAT ncRNA. UG repeat lengths are shown in pink bars and 
crosslink clusters are shown as black bars. Analysis of MIAT exon 10 inclusion (gel 
electropherogram, left, and quantification, right) in control and TDP-43 knockdown SH-
SY5Y cells is shown below. (b) TDP-43 crosslinking in MEF2D protein-coding 
transcript. UG repeat lengths are shown in pink bars and crosslink clusters are shown as 
black bars. Analysis of MEF2D exon 11 inclusion (gel electropherogram, left, and 
quantification, right) in control and TDP-43 knockdown SH-SY5Y cells is shown below. 
(c) Analysis of BIM exon 3 splicing (gel electropherogram, left, and quantification, right) 
in control and TDP-43 knockdown SH-SY5Y cells, and in healthy (C23, C25, C30) and 
FTLD-TDP (F19, F20, F21) brain samples. 
 
Table 1: Significant GO terms of the exons regulated by TDP-43.  
 
Table 2: Neuronal functions of proteins encoded by the alternative mRNA isoforms 
regulated by TDP-43.  
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Methods 
 
iCLIP analysis 
The iCLIP protocol was performed as described previously10, with the following 
modifications. TDP-43 was immunoprecipitated with protein A Dynabeads (Invitrogen) 
conjugated to rabbit-anti TDP-43 (Proteintech, 10782-2-AP). For iCLIP of CELF2, 
protein G Dynabeads conjugated to mouse anti-CELF2 (Sigma, C9367) were used. In 
both cases, the region corresponding to 55-100kDa complexes was excised from the 
membrane to isolate the RNA. High-throughput sequencing using Illumina GA2 was 
done using 54 or 72 cycles (Supplementary Table S1). The barcode sequences 
corresponding to the individual experiment were as described (Supplementary table 1). 
The random barcodes were registered and the barcodes were removed before mapping the 
sequences to the human genome sequence (version GRCh37/hg19) allowing one 
mismatch using Bowtie version 0.10.1 (command line: -a -m 1 -v 1). 
 
Nucleocytoplasmic fractionation 
50mg of crosslinked SH-SY5Y cells or brain tissue was resuspended in cold 1ml of 
cytoplasmic lysis buffer (50 mM Tris-HCl, pH 7.4, 10mM NaCl, 0.5% NP-40, 0.25% 
Triton X-100, 1mM EDTA, 0.5% RNAsin). After rotation in cold room for 5 minutes, 
homogeniser was used to complete the lysis. After centrifugation at 4°C, 3000 x g for 5 
minutes, supernatant was collected and centrifugation was repeated at 4°C, 10000 x g for 
10 minutes. Supernatant was collected, and 200ul of 0.5% SDS, 0.25% sodium 
deoxycholate, 0.5M NaCl was added; this was used as cytoplasmic fraction for CLIP or 
western blot analyses. The pellet (after 3000 x g spin) was resuspended in 1ml of CLIP 
Lysis Buffer10, sonicated and used as nuclear fraction for CLIP or western blot analyses. 
The radioactive CLIP protein-RNA complexes on nitrocellulose membrane were 
quantified using phosphoimager. 
 
Sequence analyses 
Analysis of reproducibility of crosslink sites was done as described previously10. 
Identification of the significant iCLIP crosslink clusters and z-score analysis of enriched 
pentamers was done as described previously38. For analysis of crosslinking to UG repeats 
of different lengths, the number of UG repeats in transcribed genome with a crosslink site 
in at least one of the last ten nucleotides is determined for each data set. Enrichment 
represents the ratio in the number of UG repeats with a crosslink site in real data 
compared to randomized data. The pentamer with highest z-scores in TDP-43 iCLIP 
(UGUGU) was used to assess the positions at which the TDP-43 binding sites were 
enriched relative to the position of crosslink sites. The genomic sequences at positions 
within 100 nts of the iCLIP crosslink site were filtered to retain only the sequence 
containing the pentamer. The sequences were aligned at each iCLIP crosslink site, and 
the number of sequences containing the pentamer was determined at each nucleotide 
position between -100 to +100 nts. Enrichment represents the ratio in the number of UG 
repeats with a crosslink site in real data compared to randomized data. 
 
siRNA knockdown 
Acell Smartpool oligos against TARDBP (E-012394-00-0005, Dharmacon) were 
transfected according to the manufacturer’s instructions (Acell, Dharmacon). Accell non-
targeting pool oligos (D-001910-10-05, Dharmacon) were used as a control. 
A-012394-14, TARDBP: 5’- GGCUCAAGCAUGGAUUCUA -3’ 
A-012394-15, TARDBP: 5’- GUCUCAAGUCAAAUGGAUU -3’ 
A-012394-16, TARDBP: 5’- GUGUUAAGUGAAAUGAUAC -3’ 
A-012394-17, TARDBP: 5’- GGGUGAUGUUCUAUUUACA -3’ 
 
Western blot 
SH-SY5Y cells were lysed in iCLIP lysis buffer and sonicated. To digest DNA, 10 μl of 
DNase (Ambion) was added per 1 ml of lysate, and incubated at 37C for 3 minutes. The 
samples were centrifuged and the supernatants were collected for Western analysis. The 
protein concentration was determined using Lowry’s Assay (Bio-RAD). Equal amounts 
of protein were loaded on 4-12% Bis-Tris gels (Invitrogen) and transferred to a 
nitrocellulose membrane. The membrane was incubated with rabbit anti-TDP-43 
antibody (Proteintech, 10782-2-AP) (1:1000 dilution). Rabbit anti-GAPDH (Cell 
Signalling) (1:5000 dilution) or anti-actin antibodies were used as a loading control. 
 
Splice-junction microarray 
A total of 6 samples were used, 3 from the siRNA control and 3 from KD. The high-
resolution AltSplice splice-junction microarrays were produced by Affymetrix, the cDNA 
samples were prepared using the GeneChip WT cDNA Synthesis and Amplification Kit 
(Affymetrix) and data was analysed with the version 3 of ASPIRE (Analysis of SPlicing 
Isoform REciprocity)10. 
  
RT-PCR 
Total RNA was extracted using RNasy Kit (Qiagen) and 200 ng of RNA was used for 
reverse transcription using Superscript III (Invitrogen) according to the manufacturer's 
instructions. For analysis of transcript levels, real-time PCR was performed using SYBR 
Green Fast PCR master mix (Applied Biosystems). For analysis of splicing, PCR was 
performed using Immomix (Bioline) using primers listed in Supplementary Table 4. The 
PCR products were visualised using QIAxcel capillary electrophoresis system (Qiagen). 
To calculate exon inclusion (I), the percentage of the peak representing exon inclusion 
was divided by the total percentage of peaks representing exon inclusion and skipping. 
Splicing change was calculated by subtracting the exon inclusion in the knockdown cells 
from the inclusion in wild-type cells (thus, a positive ∆I represents exons enhanced by 
TDP-43, and negative those silenced by TDP-43). 
 
RNA splicing map 
In order to analyze the impact of TDP-43 positioning on splicing regulation, we assessed 
the positioning of crosslink clusters in proximity of the exon/intron boundaries of 
alternative exons and flanking exons, including 50 nt of exonic and 500 nt of intronic 
sequence. All cassette exons with identified splicing change in knockdown SH-SY5Y 
cells and at least one significant crosslink cluster in the analysed regions are shown in the 
RNA splicing map. 
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Supplementary Figure Legends 
 
Supplementary Figure 1: Analysis of TDP-43 crosslinking to RNAs in nuclei and 
cytoplasm. (a) TDP-43 and GAPDH Western analysis of extracts used for CLIP as 
shown in Fig 1a. (b) To analyse the proportion of TDP-43 RNA complexes isolated by 
iCLIP from nuclei and cytoplasm, 32P-labelled RNA bound to TDP-43 gel was isolated 
from crosslinked healthy or FTLD-TDP samples and with high RNAse condition. 
Radioactivity was quantified using phosphoimager, and average and standard deviation 
are shown on the right. (c) Western blot analysis of GAPDH and TDP-43 was used as a 
control of successful fractionation. (d) The proportion of cDNAs (out of all cDNAs that 
mapped to human genome) from the TDP-43 iCLIP experiments in nuclear or 
cytoplasmic fraction of SH-SY5Y cells that mapped to different RNA regions. (e) 
Analysis of UGUGU enrichment positions compared to randomised data around TDP-43 
crosslink sites from iCLIP experiments in nuclear or cytoplasmic fraction of SH-SY5Y 
cells. (f) iCLIP cDNA counts for TDP-43 crosslink positions in the region of 
chromosome 11 that contains the NEAT1 and MALAT1 genes in three biological replicate 
experiments from SH-SY5Y cell line. The blue bars represent sequences on the sense 
strand of the genome, and the height of the bars corresponds to the cDNA count at 
individual crosslink sites. 
 
Supplementary Figure 2: Comparison of iCLIP binding with mRNA expression. The 
log2 healthy/FTLD-TDP brain ratios of cDNA counts within the 3’UTR are shown for 
mRNAs with at least 10 cDNAs identified both in iCLIP and in mRNAseq in either 
healthy or FTLD-TDP brain. The plot areas corresponding to an at least two-fold change 
both in iCLIP and mRNAseq are shaded in blue, whereas those with opposite change are 
shaded in green. 
 
Supplementary Figure 3: Analysis of experimental overlap. (a-c) z-scores of 
pentamer occurrence withinthe 61 nt sequence surrounding crosslink sites (-30 nt to +30 
nt) are shown for comparisons of iCLIP experiments from different samples. The 
sequences of the two most enriched pentamers and the Pearson correlation coefficient (r) 
between the two samples are given. (d) Overlap of binding to the TDP-43 crosslinking 
clusters between healthy and FTLD-TDP brain samples, depending on the number of 
cDNAs that mapped to the crosslinking clusters in healthy brain. (e) Overlap of binding 
to the TDP-43 crosslinking clusters between SH-SY5Y and hES cell lines, depending on 
the number of cDNAs that mapped to the crosslinking clusters in SH-SY5Y cells. (c) 
Overlap of binding to the TDP-43 crosslinking clusters between healthy brain and hES 
cell lines, depending on the number of cDNAs that mapped to the crosslinking clusters in 
SH-SY5Y cells. (f) Overlap of binding to the TDP-43 crosslinking clusters between SH-
SY5Y and hES cell lines, depending on the number of cDNAs that mapped to the 
crosslinking clusters in SH-SY5Y cells. 
 
Supplementary Figure 4: UGUGU enrichment in different types of RNAs. Analysis 
of positions of UGUGU enrichment compared to randomised data in all TDP-43 iCLIP 
experiments (all data grouped) in different RNAs. 
 
Supplementary Figure 5: Analysis of predictive value of iCLIP crosslink clusters 
and UG repeats.  (a) Western blots validation of TDP-43 knockdown in SH-SY5Y cells. 
Analysis of TDP-43 protein levels in mock-depleted and TDP-43-depleted SH-SY5Y 
cells with TDP-43 antibody. Actin antibody is used as a loading control. (b) The map of 
iCLIP crosslink clusters at positions within 500 nt of alternative exons and flanking 
exons that predicted TDP-43 regulated exons. The exons with 1 >⏐∆Irank⏐≥ 0.3 that 
were validated by RT-PCR are shown (red clusters in enhanced and blue clusters in 
silenced exons). Group 1 is identified by clusters in the region 150-0 nt upstream of the 
exon, group 2 by clusters in the region within 150nt upstream of the exon, but not 
upstream of the exon. (c) RT-PCR validated TDP-43 regulated alternative splicing events 
as predicted by UG-rich sequences within defined intronic and exonic regions 
surrounding alternative exons. At least 13 nucleotides had to be part of GUG or UGU 
trimers within a 30 nt sliding window in order to be considered as a UG-rich sequence. 
The UG-rich sequences are shown within 50 nt of exon and 200 nt of intron surrounding 
intron/exon boundaries in red if exon inclusion is enhanced by TDP-43, and in blue if it is 
silenced by TDP-43. Example PCR gels are shown for each exon, together with charts 
representing the levels of alternative exon inclusion and skipping in control (Ctr) and 
TDP-43 knockdown (KD) SH-SY5Y cells. 
 
Supplementary Figure 6: iCLIP binding sites in previously identified TDP-43 
targets. hES iCLIP cDNA counts are shown for a variety of previously studied TDP-43 
targets and other RNAs of interest. Crosslinking to the sense strand is represented by 
purple cDNA bars, and orange represents crosslinking to the antisense strand. Significant 
cDNA clusters (FDR < 0.05) are indicated by black bars above the cDNA counts. 
Exon/intron structure of the transcript is indicated below. In the first panel, the alternative 
exon 9 is marked by a box and the RNA sequence underlying the TDP-43 binding cluster 
is given below (UG and GU motifs in pink). 
 
 
Supplementary Table S1. Experimental annotation and barcoding. 
 
Supplementary Table S2. Mapping information for iCLIP data. 
 
Supplementary Table S3. RNA regions with a significant, greater than 0.025% 
change in proportion of cDNAs between control and FTLD-TDP brain (p value < 
0.05 by Student's t-test, one-tailed, unequal variance). 
 
Supplementary Table S4. RT-PCR primers for validation of splicing events 
identified by the microarray, iCLIP crosslink clusters or UG repeats. 
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Table 1: Significant GO terms of the exons regulated by TDP-43.  
 
GO term p-value reference exons 
TDP-43 regulated exons 
 
organ 
morphogenesis <0.001 811 13
BCL2L11_E5, COL4A3BP_E12, CTNND1_E30, 
DLC1_E2, FGFRL1_E4, FZD6_E2, MACF1_E68, 
MEF2D_E11, PLEKHA1_E21, PLEKHA1_E23, 
TFAP2A_E2, TLE1_E10, TPM1_E7 
neural tube 
closure 0.001 45 3 DLC1_E2, FZD6_E2, TFAP2A_E2 
homeostasis of 
number of cells 0.01 187 4 BCL2L11_E5, RPS24_E11, RPS24_E9, SOX6_E9 
mitotic cell 
cycle 0.016 856 9 
CLIP1_E33, HORMAD1_E4, KIF2A_E19, 
MYO16_E8, PMF1_E2, PSMD6_E4, RBM38_E3, 
SIRT7_E9, STAG2_E36 
cell surface 
receptor linked 
signaling 
pathway 
0.018 2005 16
ANXA1_E2, BRD8_E24, CNTFR_E2, CTNND1_E30
FZD6_E2, GRM4_E7, HOMER2_E5, IRAK3_E2, 
MACF1_E68, MADD_E40, PILRB_E25, 
PLEKHA1_E21, PLEKHA1_E23, PTPRD_E78, 
TLE1_E10, TNIK_E15 
chordate 
embryonic 
development 
0.021 475 6 BCL2L11_E5, COL4A3BP_E12, DLC1_E2, FZD6_E2, SOX6_E9, TFAP2A_E2 
lipid transport 0.037 276 4 ANXA1_E2, ATP11C_E36, COL4A3BP_E12, STARD4_E5 
 
Table 2: Neuronal functions of proteins encoded by the alternative mRNA isoforms 
regulated by TDP-43.  
 
Gene 
symbol Gene name 
neurologic disease 
association neuronal function 
Pubmed 
PMID 
AP2 
(TFAP2A) 
transcription factor 
AP-2 alpha   
cranial neural-tube 
closure 11137286 
BIM 
(BCL2L11) 
bcl-2 interacting 
mediator of cell 
death 
ischemia-induced 
neuronal death 
apoptotic signalling 
cascade 
16780816 
17568190 
CNTFR ciliary neurotrophic factor receptor 
Amyotropic lateral 
sclerosis  neuronal survival 19386761 
MADD 
MAP-kinase 
activating death 
domain 
Alzheimer's 
disease 
neuronal survival 
under stress 
conditions 
9482930 
MEF2D myocyte enhancer factor 2D 
Parkinson's 
disease neuronal survival 19119233 
CDK5RAP2 
CDK5 regulatory 
subunit associated 
protein 2 
Primary autosomal-
recessive 
microcephaly 
maintainance of the 
neural progenitor 
pool 
20471352 
CTNND1 delta catenin  
mental retardation 
syndrome Cri-du-
Chat 
maintenance of 
dendritic spines  19914181 
DLC1 deleted in liver cancer 1   
neural tube 
development 15710412 
FZ3 (FZD3) frizzled homolog 3   axonal guidance, neural tube closure  16495441 
KIF2A kinesin family member 2A   axonal branching  12887924 
KIF1B kinesin family member 1B  
Charcot-Marie-
Tooth neuropathy 
axonal vesicle 
transport 11389829 
SOX6  transcription factor SOX-6   
cortical interneuron 
development 19657336 
TLE1 transducin-like enhancer of split 1   
cortical neuron 
differentiation 16314515 
TNIK  TRAF2 and NCK interacting kinase   dendrite formation 20159449 
UNC5C  unc-5 homolog C (netrin receptor)   
spinal accessory 
motor neuron 
development 
17543537 
 
